This site requires Javascript.

Please enable Javascript before proceeding:

Firefox

  1. In the FireFox address bar, type about:config.
  2. Look for the javascript.enabled setting.
  3. Set it to true by right-clicking and pressing toggle.

Internet Explorer

  1. On the Tools menu, click Internet Options, then click the Security tab.
  2. Click the Internet Zone.
  3. If you do not have to customize your Internet security settings, click Default Level. Then do step 4.
  4. If you have to customize your Internet security settings, follow these steps:
    a. Click Custom Level.
    b. In the Security Settings - Internet Zone dialog box, click Enable for Active Scripting in the Scripting section.
  5. Click the Back button to return to the previous page, and then click the Refresh button to run scripts.

Chrome

  1. In the Chrome address bar, type chrome://settings/content/javascript.
  2. Adjust the toggle so that javascript is allowed.
  3. Close the Settings tab and Refresh the page.

 

Committee

Dennis Kim, Co-chair

John Kuruvilla, Co-chair

Peter Anglin (Southlake Regional Health Centre)

Meredith Giuliani (Princess Margaret)

Vikas Gupta (Princess Margaret)

David Hodgson (Princess Margaret)

Jonas Mattsson (Princess Margaret)

Christine Chen ((Princess Margaret)

Anthony Naassan (Lakeridge Health)

Ying Ling (William Osler)

Janet MacEachern (Grand River Hospital)


Co-Chairs

David Hodgson MD, MPH, FRCPC

David Hodgson MD, MPH, FRCPC

Princess Margaret Cancer Centre; University of Toronto; International Lymphoma Radiation Oncology Group (ILROG); Children’s Oncology Group; US Childhood Cancer Survivor Study

Dr. David Hodgson is a Professor and vice-Chair for research in the Department of Radiation Oncology, University of Toronto.

In addition to practicing radiation oncology at the Princess Margaret Cancer Centre, Dr. Hodgson is a founding member of the International Lymphoma Radiation Oncology Group (ILROG), serves on the Hodgkin Lymphoma Steering Committee of the Children’s Oncology Group and the Scientific Advisory Committee of the US Childhood Cancer Survivor Study. His research is primarily focused on improving the treatment of pediatric and young adult patients, specifically by better understanding the long-term late effects of treatment and how they relate to optimally managing contemporary patients.

Dennis Kim MD, FRCPC

Dennis Kim MD, FRCPC

Princess Margaret Cancer Centre; University of Toronto

Dr. Dennis Kim, Head of the Malignant Hematology Program for the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre. Dr. Dennis Kim is a Malignant Hematologist at Princess Margaret Cancer Centre and a Professor in the Department of Medicine at the University of Toronto. Dr. Kim obtained his PhD in Hematology in 2004 from the Kyungpook National University School of Medicine, South Korea. Dr. Kim has over 300+ publications including multiple landmark papers published in Blood, Journal of Clinical Oncology, Leukemia, Haematologica etc., as well as numerous published abstracts and book chapters. He has 3 major subjects of research: 1) genomics in leukemia including chronic and acute myeloid leukemia, 2) genomic-based leukemia monitoring in leukemia/hematopoietic stem cell transplantation (HCT), 3) post-transplant relapse and its mechanism, and 4) clinical trial development in chronic myeloid leukemia (CML).

John Kuruvilla, MD, FRCPC

John Kuruvilla, MD, FRCPC

Princess Margaret Cancer Centre; University of Toronto; Canadian Cancer Trials Group (CCTG); Lymphoma Canada

Dr. John Kuruvilla is a Professor of Medicine at the University of Toronto and a hematologist in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre (PM) in Toronto. He is a member of the Lymphoma, Autologous Transplant and Immune Effector Cell Therapy programs. He is also the Co-Director of the High Definition Therapeutics Strategic Pillar for PM.

Dr. Kuruvilla’s research interest is the development of novel therapeutics in lymphoid malignancies and incorporating translational research into clinical trials. He is the Lymphoma Co-Chair for the Canadian Cancer Trials Group (CCTG) as well as the Chair of the Scientific Advisory Board of Lymphoma Canada.

In his role as Multidisciplinary Clinical Lead, John Kuruvilla will work with all members of the Lymphoma/Myeloma site group to articulate a shared vision as it relates to care delivery, research, and education, be responsible for ensuring a high-quality and excellent patient experience, and actively support and promote research and quality initiatives within the site group.

Event Dates & Times

Thursday March 26, 2026
8:00 am - 5:30 pm EDT

Friday March 27, 2026
7:30 am - 5:30 pm EDT

Saturday March 28, 2026
8:00 am - 1:30 pm EDT

Event Location

Courtyard Toronto Downtown Hotel
475 Yonge St,
Toronto, ON
M4Y 1X7

Key Dates

December 16th:
Registration Opens

December 16th:
Call for Abstracts Opens

January 26th:
Deadline for Abstract Submission

End of February:
Abstract Results

Information & Assistance

Conference Services
conferences@uhn.ca